These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 9668586

  • 1. Effect of oral iron chelator L1 on iron absorption in man.
    Dresow B, Fischer R, Nielsen P, Gabbe EE, Piga A.
    Ann N Y Acad Sci; 1998 Jun 30; 850():466-8. PubMed ID: 9668586
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
    Whiteside DP, Barker IK, Conlon PD, Tesoro A, Thiessen JJ, Mehren KG, Jacobs RM, Spino M.
    J Avian Med Surg; 2007 Jun 30; 21(2):121-9. PubMed ID: 18065133
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken.
    Whiteside DP, Barker IK, Conlon PD, Tesoro A, Thiessen JJ, Mehren KG, Jacobs RM, Spino M.
    J Avian Med Surg; 2007 Jun 30; 21(2):110-20. PubMed ID: 18065132
    [Abstract] [Full Text] [Related]

  • 4. Acute iron intoxication: the efficacy of deferiprone and sodium biocarbonate in the prevention of iron absorption from the digestive tract.
    Barr J, Berkovitch M, Tavori I, Kariv N, Schejter A, Eshel G.
    Vet Hum Toxicol; 1999 Oct 30; 41(5):308-11. PubMed ID: 10509434
    [Abstract] [Full Text] [Related]

  • 5. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Int J Clin Pharmacol Ther; 1996 Jul 30; 34(7):288-92. PubMed ID: 8832304
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A, Alder V, Robertson D, Papadimitriou J, Maserei J, Berdoukas V, Kontoghiorghes G, Taylor E, Baker E.
    Biometals; 1997 Oct 30; 10(4):247-56. PubMed ID: 9353871
    [Abstract] [Full Text] [Related]

  • 8. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
    Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, Koren G, Brittenham GM, Gordeuk VR.
    Am J Trop Med Hyg; 1998 Mar 30; 58(3):358-64. PubMed ID: 9546419
    [Abstract] [Full Text] [Related]

  • 9. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.
    Matsui D, Klein J, Hermann C, Grunau V, McClelland R, Chung D, St-Louis P, Olivieri N, Koren G.
    Clin Pharmacol Ther; 1991 Sep 30; 50(3):294-8. PubMed ID: 1914364
    [Abstract] [Full Text] [Related]

  • 10. Clinical trials with oral iron chelator L1.
    Kontoghiorghes GJ, Hoffbrand AV.
    Lancet; 1991 Sep 30; 2(8678-8679):1516-7. PubMed ID: 2574781
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one.
    Pangjit K, Banjerdpongchai R, Phisalaphong C, Fucharoen S, Xie YY, Lu ZD, Hider RC, Srichairatanakool S.
    J Pharm Pharmacol; 2015 May 30; 67(5):703-13. PubMed ID: 25627251
    [Abstract] [Full Text] [Related]

  • 13. Methodological issues in studying the effect of the new oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on absorption of iron.
    Bentur Y, Klein J, Levy M, Olivieri N, McGuigan M, Koren G.
    Vet Hum Toxicol; 1990 Apr 30; 32(2):159-61. PubMed ID: 2327067
    [Abstract] [Full Text] [Related]

  • 14. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
    Brissot P, Bolder U, Schteingart CD, Arnaud J, Hofmann AF.
    Hepatology; 1997 Jun 30; 25(6):1457-61. PubMed ID: 9185768
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Iron mobilisation from transferrin by deferiprone (L1).
    Kontoghiorghes GJ, Kolnagou A, Eracleous E, Evans RW.
    Br J Haematol; 2005 Apr 30; 129(1):157. PubMed ID: 15801969
    [No Abstract] [Full Text] [Related]

  • 17. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
    Jirasomprasert T, Morales NP, Limenta LM, Sirijaroonwong S, Yamanont P, Wilairat P, Fucharoen S, Chantharaksri U.
    Free Radic Res; 2009 May 30; 43(5):485-91. PubMed ID: 19353420
    [Abstract] [Full Text] [Related]

  • 18. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 30; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP.
    Clin Pharmacokinet; 2011 Jan 30; 50(1):41-50. PubMed ID: 21028920
    [Abstract] [Full Text] [Related]

  • 20. Effect of the oral iron chelator deferiprone in diabetic nephropathy rats.
    Zou C, Liu X, Liu R, Wang M, Sui M, Mu S, Li L, Ji L, Xie R.
    J Diabetes; 2017 Apr 30; 9(4):332-340. PubMed ID: 27121697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.